Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Epizyme, Inc. (NASDAQ: EPZM).

Full DD Report for EPZM

You must become a subscriber to view this report.


Recent News from (NASDAQ: EPZM)

Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 trials of its lead candidate, tazemetostat, a potent, selective, orally available EZH2 inhibitor, wi...
Source: GlobeNewswire
Date: May, 17 2018 09:13
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Enrollment of Patients Completed in Multiple Tazemetostat Combination Studies EU Orphan Designations Received for Tazemetostat Conference Call to be Held on May 17, 2018 at 9:30 a.m. ET CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-s...
Source: GlobeNewswire
Date: May, 08 2018 07:30
Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
First Quarter 2018 Financial Results to be Announced May 8, 2018 Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage compa...
Source: GlobeNewswire
Date: May, 01 2018 07:30
Midday Gainers / Losers (04/24/2018)
Gainers: CHEK +69% . ATOS +40% . LEDS +22% . CLDC +20% . SANM +18% . HSII +17% . HLX +16% . SC +16% . MARA +12% . LYL +11% . More news on: Check-Cap Ltd., Atossa Genetics, Inc., SemiLEDs Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 24 2018 12:40
Today's Research Reports on Trending Tickers: Epizyme and Valeant Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / April 24, 2018 / U.S. markets continued to slump on Monday as technology stocks fell, with Facebook, Amazon, Netflix and Alphabet all closing in the red, and interest rates continued to rise. The yield on the 10-year Treasury note touched a high of 2.99 percent. ...
Source: ACCESSWIRE IA
Date: April, 24 2018 08:30
Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's Mixed Advisory Panel Vote
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Orexigen Therapeutics To Sell Itself To Nalpropion Pharmaceuticals For $75 Million News: Recently, Orexigen Therapeutics ( OREX ) announced that it w...
Source: SeekingAlpha
Date: April, 24 2018 01:51
Epizyme Provides Update Regarding Tazemetostat Clinical Program
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report of...
Source: GlobeNewswire
Date: April, 23 2018 16:45
Recent Analysis Shows Photronics, Just Energy Group, Baidu, Nomura Holdings Inc ADR, KT, and Epizyme Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Photronics, Inc. (NASDAQ:PLAB), Just Energy Group, Inc. (NYSE:JE), Baidu...
Source: GlobeNewswire
Date: April, 11 2018 07:55
Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the effects of EZH2 inhibition in patients with advanced solid tumors and B-cell non-Hodgkin lymp...
Source: GlobeNewswire
Date: April, 09 2018 18:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1716.2516.9517.3516.201,119,532
2017-02-0210.3011.2511.7010.05852,212
2017-02-0110.5510.3010.8010.15199,177
2017-01-319.6510.5010.609.60255,771
2017-01-3010.059.7510.059.65170,466

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1326,48150,77152.1577Short
2018-08-1012,21331,41238.8800Short
2018-08-0944,04260,14873.2227Short
2018-08-0841,32778,55752.6077Short
2018-08-0753,309106,91349.8620Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EPZM.


About Epizyme, Inc. (NASDAQ: EPZM)

Logo for Epizyme, Inc. (NASDAQ: EPZM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EPZM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 05 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 05 2018
      Automatic shelf registration statement of securities of well-known seasoned issuers
      Filing Type: S-3ASRFiling Source: edgar
      Filing Date: April, 05 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 03 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 03 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: EPZM)

      Daily Technical Chart for (NASDAQ: EPZM)


      Stay tuned for daily updates and more on (NASDAQ: EPZM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EPZM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EPZM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EPZM and does not buy, sell, or trade any shares of EPZM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/